phrykt

HCW Biologics Inc. (HCWB): who owns it and who trades it

As of Nov 16, 2026, HCWB insiders reported 5 purchases worth $512K in the last 12 months. The largest buyer was Scott T Garrett (Director), with $251K. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling HCW Biologics

From the latest filings

Overall: more buying than selling. Insiders and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Insider trades

In the last 12 months, HCWB insiders reported $512K of open-market purchases and $0 of sales.

Purchases, 12 months
$512K
5 trades, 4 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Jul 29, 2026
Filed Jul 31, 2026

Purchases and sales by month

$432K$432KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jul 29, 2026Hing C WongCEOPurchase23,210$2.59$60.1KForm 4
Jul 29, 2026Lee FlowersVice presidentPurchase7,736$2.59$20KForm 4
May 22, 2026Hing C WongCEOPurchase113,879$1.41$161KForm 4
May 22, 2026Scott T GarrettDirectorPurchase177,936$1.41$251KForm 4
May 22, 2026Rebecca ByamCFOPurchase14,235$1.41$20.1KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Scott T GarrettDirector$251K–May 22, 2026
Hing C WongChief Executive Officer, Director, 10% owner$221K–Jul 29, 2026
Rebecca ByamChief Financial Officer$20.1K–May 22, 2026
Lee FlowersSVP of Business Development$20K–Jul 29, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

HCWB short interest

Low short interest. 2.7% of HCWB shares are sold short: about 1 share in 37. Over the last 12 reports the number of shares short went down 99%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 49,290 HCWB shares were sold short, 2.7% of the shares outstanding, up 30.7% from the report before. At the average daily volume of 57,290 shares, buying them all back would take about 1.0 trading days (days to cover).

Shares short, % of all shares

2.68%May 15Oct 3065.6%

Days to cover

1.0May 15Oct 301.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202649,2902.68%+31%57,2901.0
Oct 15, 202637,7092.05%-38%226,1241.0
Sep 30, 202660,9413.32%+557%1.35M1.0
Sep 15, 20269,2740.51%-73%414,3371.0
Aug 31, 202634,1361.86%+138%238,7741.0
Aug 14, 202614,3480.78%-32%80,1651.0
Jul 31, 202620,9790.31%-30%71,0921.0
Jul 15, 202629,9600.44%-28%46,2661.0
Jun 30, 202641,7090.62%-86%197,5731.0
Jun 15, 2026296,8144.41%-29%1.12M1.0
May 29, 2026417,9606.21%-89%32.63M1.0
May 15, 20263.84M57.09%+573%39.01M1.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

HCW Biologics company events

HCW Biologics filed 28 reports on Form 8-K in the last 12 months, 4 of them about an important change (restatement, listing). The latest was on Nov 5, 2026.

  1. Nov 5, 2026AgreementHCW Biologics Inc. entered into a Notes Purchase Agreement with Streeterville Capital, LLC, providing for the issuance of two secured promissory notes: (i) a Promissory Note A-1 in the original principal amount of $3.2 million and (ii) a Promissory Note B in the original principal amount of $7.0… Filing
  2. Sep 24, 2026AgreementHCW Biologics Inc. entered into a Securities Purchase Agreement with an existing institutional investor, pursuant to which the Company agreed to issue and sell an aggregate of 903,614 units, with each Unit consisting of (i) one pre-funded warrant to purchase one share of the Company’s common stock… Filing
  3. Sep 10, 2026AnnouncementHCW Biologics Inc. filed Amendment No. 1 to Preliminary Proxy Statement, which amends and restates the Preliminary Proxy Statement originally filed with the Securities and Exchange Commission on September 8, 2026. Filing
  4. Sep 8, 2026AgreementHCW Biologics Inc. entered into an Exclusive Distribution Agreement with Akron Biotech, a leading manufacturer of ancillary materials and a contract development and manufacturing organization for the distribution of the Company’s commercial-ready molecule, HCW11-006, for use as a reagent in cell… Filing
  5. Aug 14, 2026ResultsReleased financial results. Filing
  6. Aug 14, 2026RestatementThe Audit Committee of the Board of Directors of HCW Biologics Inc., in consultation with management and the Company’s independent registered public accounting firm, Crowe LLP, concluded that the Company’s previously issued unaudited condensed financial statements as of and for the three months… Filing
  7. Jul 29, 2026AgreementHCW Biologics Inc. entered into a Securities Purchase Agreement with certain accredited investors (each, an investor, and collectively, the “Investors”), pursuant to which the Company agreed to issue and sell an aggregate of 618,682 units, with each Unit consisting of (i) one share of the Company’s… Filing
  8. Jul 1, 2026AnnouncementIn the three months ending June 30, 2026, HCW Biologics Inc. will report a settlement and extinguishment of $2.8 million of disputed accounts payable. Filing
  9. Jun 30, 2026ListingHCW Biologics Inc. received written notice form the Listing Qualifications Staff of the Nasdaq Capital Market Nasdaq Stock Market LLC that the Nasdaq Hearings Panel found that the Company regained compliance with Listing Rule 5550(a)(2), the “Bid Price Rule,” per the terms set forth in the Panel’s… Filing
  10. Jun 26, 2026SharesChanged the rights of its shareholders. Filing
  11. Jun 16, 2026AnnouncementShared information with investors. Filing
  12. Jun 15, 2026VoteReported shareholder vote results. Filing
  13. Jun 1, 2026ListingAs previously disclosed, on March 26, 2026, HCW Biologics Inc. received written notice from the Listing Qualifications Staff of the Nasdaq Stock Market LLC that for 30 consecutive business days, the Company’s listed securities did not maintain a minimum bid price of $1 per share, in accordance with… Filing
  14. May 27, 2026AgreementEnded an important agreement. Filing
  15. May 21, 2026AgreementHCW Biologics Inc. entered into a Securities Purchase Agreement with certain accredited investors, pursuant to which the Company agreed to issue and sell an aggregate of 2,846,975 units, with each unit consisting of (i) one share of the Company’s common stock, par value $0.0001 per share, at a… Filing
  16. May 14, 2026ResultsReleased financial results. Filing
  17. Apr 30, 2026AnnouncementHCW Biologics Inc. convened a Special Meeting of its Stockholders. Filing
  18. Apr 30, 2026AnnouncementHCW Biologics Inc. determined that it would enter into a consulting agreement with I.R. Agency LLC in which the Company will agree to engage the Market Consultant for future marketing efforts to be determined by management of the Company in its discretion, to communicate information about the… Filing
  19. Apr 16, 2026RulesChanged its bylaws or articles. Filing
  20. Mar 31, 2026ResultsReleased financial results. Filing
  21. Mar 17, 2026AgreementHCW Biologics Inc. issued a press release announcing the closing of its exclusive worldwide license for its molecule, HCW11-006, and the receipt of full payment of the upfront license fee. Filing
  22. Mar 2, 2026ListingThe HCW Biologics Inc. received written notice form the Listing Qualifications Staff of the Nasdaq Capital Market Nasdaq Stock Market LLC that the Nasdaq Hearings Panel found that the Company regained compliance with all continued listing rules of the Nasdaq Capital Market, according to the terms… Filing
  23. Feb 19, 2026AgreementHCW Biologics Inc. entered into a securities purchase agreement with a single institutional investor pursuant to which the Company agreed to offer and sell, in a follow-on public offering, 2,477,292 units consisting of (i) 2,477,292 shares of the Company’s common stock, $0.0001 par value per share… Filing
  24. Feb 13, 2026AgreementHCW Biologics Inc. and WY Biotech Co., Ltd., a China-based company specializing in the early-stage development of recombinant protein drugs and gene/cell therapies, today jointly announced the commencement of an exclusive worldwide license agreement covering the development and commercialization… Filing
  25. Dec 31, 2025AnnouncementAs previously disclosed, on August 19, 2025, HCW Biologics Inc. was notified by the Listing Qualifications Staff of The Nasdaq Stock Market LLC that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires the maintenance of $2.5 million in stockholders’ equity for… Filing
  26. Nov 20, 2025AgreementHCW Biologics Inc. entered into an inducement offer agreement with a single institutional investor, pursuant to which the Company agreed to reduce the exercise price of the outstanding warrants held by the Investor, issued in November 2024 and May 2025 (the “May 2025 Warrants” together with the… Filing
  27. Nov 19, 2025AgreementHCW Biologics Inc. and Beijing Trimmune Biotech Co., Ltd. entered into an Amended and Restated License, Research and Co-Development Agreement following the assignment of the original License, Research and Co-Development Agreement, which includes an exclusive license to HCW11-006 for in vivo… Filing
  28. Nov 18, 2025AnnouncementShared information with investors. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

HCW Biologics financials

Famous investors that hold HCWB

1 of the 50 well-known investors we track reported holding HCWB in their latest 13F filing. The largest position is Ken Griffin's, worth $76.6K.

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 202644,818$76.6K0.0%+125%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named HCWB in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Armistice Capital, LLC13G10.0%
Nov 16, 2026Armistice Capital, LLC13G10.0%

Questions about HCW Biologics Inc. (HCWB) stock

Are HCWB insiders buying or selling?

In the last 12 months, HCWB insiders reported 5 open-market purchases worth $512K and no sales. The latest trade was on Jul 29, 2026. See every trade.

What is the short interest in HCWB?

As of Oct 30, 2026, 49,290 HCWB shares were sold short, 2.7% of the shares outstanding, up 30.7% from the report before. At the average daily volume of 57,290 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.

Which famous investors hold HCWB?

1 of the 50 well-known investors we track reported HCWB in their latest 13F filing, including Ken Griffin. The largest position is worth $76.6K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.